25-Year follow-up of HIV-positive patients with benign lymphoepithelial cysts of the parotid glands: A retrospective review

Waleed F. Mourad, Rebekah Young, Rafi Kabarriti, Dukagjin M. Blakaj, Rania A. Shourbaji, Jonathan Glanzman, Shyamal Patel, Nitin Ohri, Ravindra Yaparpalvi, Jonathan J. Beitler, Shalom Kalnicki, Madhur K. Garg

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Aim: To report long-term outcomes for HIV-positive patients who underwent radiation therapy (RT) for benign lymphoepithelial cysts (BLEC) of the parotid glands. Patients and Methods: In this single institution retrospective study of HIV-associated BLEC of the parotids, the medical records of 37 HIV-positive patients who were treated with RT between 1987-2012 were reviewed. Patients were stratified into two groups; group A consisted of 15 patients (40.5%) who received a total dose of ≤18Gy, with a median dose 10 Gy (range 8-18Gy), and group B consisted of 22 patients (59.5%) who received a total dose of 24 Gy. In addition to dosing information, additional patient data were collected, including demographics, HAART compliance, follow-up, and re-treatment status. Results: The median age at the time of treatment was 41 (range=7-70) years. With a median follow-up of 35 (range=12-75) months for the entire cohort, the complete response (CR) and partial response (PR) rates were 35% and 8%, respectively. All but one of 15 patients in Group A (lower total dose) eventually experienced local failure with the re-emergence of parotid hypertrophy. Among the patients in group B (higher total dose of 24 Gy), 55%, 13%, and 32% experienced CR, PR, and LF, respectively. Median times to failure in groups A and B were 7 and 20 months, respectively (p<0.0001). Similarly, logistic regression test revealed the higher dose to be associated with better response rate (i.e. CR or PR) (p<0.0001), which was also statistically significant (p=0.03) after adjusting for confounding variables (age, race, gender, HAART use, and fractionation). Conclusion: A total dose of 24 Gy continues to be recommended for durable cosmetic control of BLEC of the parotid glands that is associated with HIV-seropositivity.

Original languageEnglish (US)
Pages (from-to)4927-4932
Number of pages6
JournalAnticancer research
Issue number11
StatePublished - Nov 2013
Externally publishedYes


  • Benign lymphoepitheilial cysts (BLEC)
  • HIV positive
  • Highly active antiretroviral therapy (HAART)
  • Parotid gland hyperplasia
  • Radiation therapy (RT)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of '25-Year follow-up of HIV-positive patients with benign lymphoepithelial cysts of the parotid glands: A retrospective review'. Together they form a unique fingerprint.

Cite this